Integrins as Therapeutic Targets: Successes and Cancers
AbstractIntegrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. View Full-Text
Share & Cite This Article
Raab-Westphal, S.; Marshall, J.F.; Goodman, S.L. Integrins as Therapeutic Targets: Successes and Cancers. Cancers 2017, 9, 110.
Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. Cancers. 2017; 9(9):110.Chicago/Turabian Style
Raab-Westphal, Sabine; Marshall, John F.; Goodman, Simon L. 2017. "Integrins as Therapeutic Targets: Successes and Cancers." Cancers 9, no. 9: 110.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.